Stay updated on XMT-1536 First-in-Human Study in NaPi2b-Expressing Cancers Clinical Trial
Sign up to get notified when there's something new on the XMT-1536 First-in-Human Study in NaPi2b-Expressing Cancers Clinical Trial page.

Latest updates to the XMT-1536 First-in-Human Study in NaPi2b-Expressing Cancers Clinical Trial page
- Check5 days agoNo Change Detected
- Check12 days agoChange DetectedSite revision updated from v3.4.1 to v3.4.2. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check19 days agoChange DetectedRevision: v3.4.1 is now displayed, replacing the previous v3.4.0.SummaryDifference0.1%

- Check27 days agoChange DetectedAdded a 'Show glossary' option and updated metadata: 'Last Update Submitted that Met QC Criteria' capitalization adjusted, 'No FEAR Act Data' added, and the Revision updated to v3.4.0 (replacing v3.3.4).SummaryDifference0.2%

- Check41 days agoChange DetectedRevision updated from v3.3.3 to v3.3.4. No study content, eligibility criteria, or results were modified.SummaryDifference0.1%

- Check63 days agoChange DetectedAdded a Locations section with Oklahoma as a trial site. This updates where the study is recruiting and participating locations are shown.SummaryDifference0.2%

- Check92 days agoChange DetectedRevision: v3.3.2 replaces the previous v3.2.0 version.SummaryDifference0.1%

Stay in the know with updates to XMT-1536 First-in-Human Study in NaPi2b-Expressing Cancers Clinical Trial
Enter your email address, and we'll notify you when there's something new on the XMT-1536 First-in-Human Study in NaPi2b-Expressing Cancers Clinical Trial page.